Table 4 Univariate analysis, multivariate analysis, and factors for building the prediction model based on chemotherapy cycles.
Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95%CI) | P | HR (95%CI) | P | |
Gender | ||||
Male | 1 | – | 1 | – |
Female | 1.05 (0.89–1.25) | 0.57 | 1.03 (0.83–1.27) | 0.81 |
Age | ||||
< 40 | 1 | 1 | – | |
40–60 | 0.8 (0.49–1.32) | 0.39 | 0.7 3(0.44–1.3) | 0.27 |
> 60 | 1.04 (0.64–1.7) | 0.87 | 0.88 (0.53–1.56) | 0.65 |
Tumor site | ||||
Unknown | 1 | – | 1 | – |
Bladder | 0.2(0.07–0.59) | < 0.001 | 0.23 (0.07–0.68) | 0.01 |
Breast | 0.25 (0.12–0.5) | < 0.001 | 0.24 (0.12–0.54) | < 0.001 |
Cervix | 1 (0.43–2.34) | 1 | 1.23 (0.49–3.1) | 0.66 |
Colorectal | 0.48 (0.25–0.91) | 0.03 | 0.42 (0.22–0.89) | 0.02 |
Esophagus | 0.31 (0.12–0.85) | 0.02 | 0.44 (0.15–1.23) | 0.13 |
Biliary | 0.85 (0.36–1.96) | 0.7 | 0.58 (0.22–1.52) | 0.26 |
Gastric | 1.05 (0.53–2.09) | 0.89 | 0.55 (0.25–1.28) | 0.15 |
Lung | 0.25 (0.13–0.5) | < 0.001 | 0.35 (0.17–0.76) | 0.01 |
Ovarian | 0.25 (0.13–0.5) | < 0.001 | 1.71 (0.78–3.93) | 0.19 |
Pancreas | 0.36 (0.17–0.77) | 0.01 | 0.41 (0.16–1.06) | 0.06 |
mpc | 0.63 (0.31–1.28) | 0.2 | 0.35 (0.16–0.8) | 0.01 |
Other | 1.24 (0.6–2.56) | 0.56 | 0.96 (0.46–2.12) | 0.92 |
Liver metastases | ||||
No | 1 | – | 1 | – |
Yes | 1.21 (1.02–1.44) | 0.03 | 1.02 (0.84–1.24) | 0.83 |
WBC | ||||
Normal | 1 | – | 1 | – |
Low | 1.8 (1.48–2.2) | < 0.001 | 1.89 (1.52–2.35) | < 0.001 |
Hb | ||||
Normal | 1 | – | 1 | – |
Low | 2.1 (1.76–2.5) | < 0.001 | 1.94 (1.6–2.36) | < 0.001 |
Unknown | 1.27 (0.79–2.05) | 0.32 | 0.87 (0.43–1.77) | 0.71 |
CRP | ||||
Normal | 1 | – | 1 | – |
High | 1.4 (1.01–1.94) | 0.05 | 1.06 (0.74–1.5) | 0.76 |
Unknown | 1.41 (1.13–1.77) | < 0.001 | 1.31 (1.03–1.67) | 0.03 |
Tbil | ||||
Normal | 1 | – | 1 | – |
High | 2.23 (1.48–3.37) | < 0.001 | 1.76 (1.1–2.76) | 0.02 |
Unknown | 1.25 (0.92–1.7) | 0.15 | 1.57 (0.83–2.81) | 0.15 |
ALB | ||||
Normal | 1 | – | 1 | – |
Low | 2.54 (1.38–4.67) | < 0.001 | 1.82 (0.91–3.44) | 0.08 |
Unknown | 1.12 (0.92–1.35) | 0.26 | 1.08 (0.88–1.34) | 0.46 |
AST | ||||
Normal | 1 | – | 1 | – |
High | 1.85 (1.52–2.27) | < 0.001 | 1.89 (1.46–2.43) | < 0.001 |
Unknown | 0.96 (0.75–1.21) | 0.71 | 0.76 (0.54–1.04) | 0.1 |
ALT | ||||
Normal | 1 | – | 1 | – |
High | 0.95 (0.73–1.23) | 0.7 | 0.74 (0.54–1.01) | 0.06 |
Unknown | 1.18 (0.82–1.7) | 0.36 | 1.64 (0.74–3.69) | 0.22 |
Oxaliplatin | ||||
No | 1 | – | 1 | – |
Yes | 2.22 (1.86–2.66) | < 0.001 | 2.57 (1.89–3.49) | < 0.001 |
Pemetrexed | ||||
No | 1 | – | 1 | – |
Yes | 0.43 (0.24–0.75) | < 0.001 | 0.5 (0.25–0.92) | 0.03 |
Irinotecan | ||||
No | 1 | – | 1 | – |
Yes | 0.63 (0.5–0.79) | < 0.001 | 1.23 (0.88–1.72) | 0.22 |
Gemcitabine | ||||
no | ||||
yes | 0.68 (0.48–0.96) | 0.03 | 0.81 (0.52–1.24) | 0.34 |
Fluorouracil | ||||
No | 1 | – | 1 | – |
Yes | 0.54 (0.43–0.68) | < 0.001 | 0.54 (0.39–0.75) | < 0.001 |
Capecitabine | ||||
No | 1 | – | ||
Yes | 2.12 (1.66–2.69) | < 0.001 | 1.45 (1.05–1.99) | 0.02 |
S-1 | ||||
No | 1 | – | 1 | – |
Yes | 2.33 (1.72–3.16) | < 0.001 | 1.1 (0.65–1.84) | 0.71 |
Fruquintinib | ||||
No | 1 | – | 1 | – |
Yes | 2.96 (1.53–5.71) | < 0.001 | 1.93 (0.85–4.19) | 0.11 |
Alkylating agents | ||||
No | 1 | – | 1 | – |
Yes | 0.27 (0.1–0.74) | 0.01 | 0.2 (0.06–0.54) | < 0.001 |
Anthracycline | ||||
No | 1 | – | 1 | – |
Yes | 1.76 (1.08–2.86) | 0.02 | 2.17 (1.1–4.2) | 0.02 |
TKI | ||||
No | 1 | – | 1 | – |
Yes | 1.53 (1.2–1.95) | < 0.001 | 1.48 (1.07–2.04) | 0.02 |
Taxane | ||||
No | 1 | – | 1 | |
Yes | 0.68 (0.53–0.87) | < 0.001 | 0.65 (0.46–0.91) | 0.01 |
Line of treatment | ||||
1 | 1 | – | 1 | – |
2 | 1.66 (1.35–2.04) | < 0.001 | 1.21 (0.95–1.54) | 0.12 |
3 | 1.82 (1.26–2.61) | < 0.001 | 1.57 (1.03–2.36) | 0.03 |
4 | 1.62 (0.76–3.43) | 0.21 | 1.26 (0.52–2.7) | 0.58 |
5 | 2.02 (0.44–9.26) | 0.36 | 1.98 (0.29–8.13) | 0.4 |
6 | 3.37 (0.35–32.46) | 0.29 | 5.78 (0.27–49.7) | 0.14 |
